Patient characteristics | Intensified myeloablative conditioning (n = 81) | Standard myeloablative conditioning (n = 104) | P-value |
---|---|---|---|
Female/Male | 31(38.3%)/50(61.7%) | 41(39.4%)/63(60.6%) | NS |
Median age, years (range) | 26(14–54) | 28(12–63) | NS |
Disease | Â | Â | Â |
  ALL | 42 (51.85%) | 23 (22.1%) | P<0.001 |
  AML | 17 (21.0%) | 43(41.4%) |  |
  ALAL | 12 (14.8%) | 12 (11.5%) |  |
  CML | 6 (7.4%) | 22 (21.2%) |  |
  HD/NHL | 3(3.7%) | 2 (1.9%) |  |
  MDS | 0 (0%) | 2 (1.9%) |  |
  BPDCN | 1 (1.25%) | 0 (0%) |  |
Disease status at the time of transplants | Â | Â | Â |
  CR (including CML-CP) | 31 (38.3%) | 94 (90.4%) | P<0.001 |
  NR (including CML-AP and BC) | 50 (61.7%) | 10 (9.6%) |  |
EBV serostatus | Â | Â | Â |
  D-/R- | 15(18.5 %) | 21(20.2 %) | NS |
  D+/R- | 23(28.4%) | 27(26.0%) |  |
  D-/R+ | 16(19.8%) | 22(21.1%) |  |
  D+/R+ | 27(33.3%) | 34(32.7%) |  |
CMV serostatus | Â | Â | Â |
  D-/R- | 4(4.9%) | 5(4.8%) | NS |
  D+/R- | 3(3.7%) | 4(3.85%) |  |
  D-/R+ | 3(3.7%) | 2(1.95%) |  |
  D+/R+ | 71(87.7%) | 93(89.4%) |  |
Donor type | Â | Â | Â |
  Sibling donor | 44(54.3%) | 73 (70.2%) | P = 0.010 |
  Family donor | 11 (13.6%) | 3 (2.9%) |  |
  Unrelated donor | 26(32.1%) | 28 (26.9%) |  |
HLA typing | Â | Â | Â |
  HLA-identical | 49 (60.5%) | 79 (76.0%) | NS |
  One allele mismatched | 15 (18.5%) | 15 (14.4%) |  |
  Two alleles mismatched | 8 (9.9%) | 8 (7.7%) |  |
  Three alleles mismatched | 1 (1.2%) | 1 (0.95%) |  |
  Four alleles mismatched | 6 (7.4%) | 1 (0.95%) |  |
  Five alleles mismatched | 2 (2.5%) | 0 (0.0%) |  |
Stem cell source | Â | Â | Â |
  PBSCs | 63 (77.8%) | 90 (86.5%) | NS |
  BM | 1 (1.2%) | 0 (0.0%) |  |
  PBSCs + BM | 17(21.0%) | 14 (13.5%) |  |
Median CD34+ cells per graft, ×106/kg (range) | 8.8(5.4-11.9) | 8.1(5.2-11.7) | NS |
Conditioning | Â | Â | Â |
  TBI + CY |  | 36 (34.6%) | NA |
  Bu + CY |  | 40 (38.5%) |  |
  Bu + Flu |  | 28(26.9%) |  |
  Flu + Ara-c + TBI + CY | 49 (60.5%) |  |  |
  TBI + CY + VP-16 | 32 (39.5%) |  |  |
GVHD prophylaxis | Â | Â | Â |
  CsA | 4 (5.0%) | 2 (1.9%) | NS |
  CsA + MTX | 33 (40.75%) | 62 (59.6%) |  |
  CsA + MTX + ATG | 28 (34. 5%) | 27 (26.0%) |  |
  CsA + MTX + MMF | 3 (3.7%) | 2 (1.9%) |  |
  CsA + MTX + ATG + MMF | 13 (16.05%) | 11 (10.6%) |  |